Tesamorelin: What the Research Shows
Also known as: Egrifta, TH9507
An FDA-approved GHRH analog used for HIV-associated lipodystrophy, with research into broader metabolic and cognitive applications.
This content is for educational purposes only and is not medical advice. Consult a qualified healthcare provider before making any health decisions. Full disclaimer
Quick Facts
Regulatory Status
FDA-approved in 2010 as Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
FDA-approved indications:
- Reduction of excess abdominal fat in HIV-associated lipodystrophy (Egrifta)
Researched Applications
Key Research (1 studies cited)
Tesamorelin, a Growth Hormone–Releasing Factor Analogue, Reduces Visceral Fat in HIV-Infected Patients
human rctFalutz J, et al. (2007) — Annals of Internal Medicine — n=412
Pivotal RCT showing tesamorelin reduced visceral adipose tissue by 15.4% in HIV patients with lipodystrophy.
Key finding: Tesamorelin reduced visceral adipose tissue by 15.4% compared to placebo, without worsening glucose tolerance.
PubMed: 17909207About this article: Written by the PeptideMark Research Team. Last reviewed 2026-03-11. All factual claims are cited to peer-reviewed sources. PubMed links open in a new tab for independent verification. Editorial methodology · Medical disclaimer
The Peptide Brief
Weekly peptide research digest. No spam.